CDC ENTEBBE

🇺🇬Uganda

Country: 🇺🇬Uganda

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

Phase 1

Recruiting

Conditions: Rotavirus Infections

Interventions: Biological: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Biological: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Other: Placebo

First Posted Date: 2024-07-03

Last Posted Date: 2024-08-12

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 50

Registration Number: NCT06485258

Locations: 🇺🇸
Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia, United States

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

Phase 4

Completed

Conditions: Malaria
Plasmodium Falciparum
Uncomplicated Malaria

Interventions: Drug: Amodiaquine-artesunate (ASAQ)
Drug: Artemether+Lumefantrine (AL)

First Posted Date: 2024-03-08

Last Posted Date: 2024-05-07

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 352

Registration Number: NCT06300970

Locations: 🇱🇷
Sinje Health Center, Garwula District, Sinje, Grand Cape Mount County, Sinje, Grand Cape Mount County, Liberia
🇱🇷
Saclepea-Mahn Comprehensive Health Center Saclepea-Mahn District, Nimba County, Saclepea, Nimba County, Liberia

Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP

Phase 3

Active, not recruiting

Conditions: Influenza

Interventions: Biological: FluQuadri
Biological: FLUAD Quadrivalent

First Posted Date: 2023-09-26

Last Posted Date: 2024-10-04

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 192

Registration Number: NCT06054269

Locations: 🇵🇪
Hospital Nacional Cayetano Heredia, Lima, Peru
🇵🇪
Hospital Nacional Arzobispo Loayza, Lima, Peru

Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

Recruiting

Conditions: Monkeypox
AIDS
HIV Infections

First Posted Date: 2023-09-21

Last Posted Date: 2024-10-07

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 100

Registration Number: NCT06045923

Locations: 🇺🇸
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Phase 2

Recruiting

Conditions: Tuberculosis, Pulmonary
Tuberculosis Infection

Interventions: Drug: Rifabutin
Drug: Delamanid
Drug: Isoniazid
Drug: Bedaquiline
Drug: Moxifloxacin
Drug: Rifampin
Drug: Pyrazinamide
Drug: Ethambutol

First Posted Date: 2023-03-13

Last Posted Date: 2024-01-08

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 288

Registration Number: NCT05766267

Locations: 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸
TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸
TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States

and more 9 locations

Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

Phase 4

Active, not recruiting

Conditions: Poliomyelitis

Interventions: Biological: Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
Biological: Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
Biological: Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
Biological: Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS

First Posted Date: 2022-07-15

Last Posted Date: 2024-08-22

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 1224

Registration Number: NCT05460377

Locations: 🇧🇩
Icddr,B Study Clinics, Dhaka, Bangladesh

Immunogenicity nOPV2 With and Without bOPV

Phase 2

Completed

Conditions: Poliomyelitis

Interventions: Biological: Novel monovalent oral poliovirus vaccine type 2 (nOPV2)
Biological: Bivalent oral poliovirus vaccine (bOPV)

First Posted Date: 2020-10-08

Last Posted Date: 2024-10-04

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 795

Registration Number: NCT04579510

Locations: 🇧🇩
Icddr,B Study Clinics, Dhaka, Bangladesh

Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: VaxigripTetra™ by Sanofi, Inc.
Biological: Flublok™ Quadrivalent by Sanofi, Inc.

First Posted Date: 2020-08-21

Last Posted Date: 2023-11-15

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 577

Registration Number: NCT04523324

Locations: 🇮🇱
Rabin Medical Center-Beilinson, Petah Tikva, Israel
🇮🇱
Soroka Medical Center, Be'er Sheva, Israel

Open Label Extension (OLE) of the TDF2 Study, Botswana

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg

First Posted Date: 2020-03-23

Last Posted Date: 2022-05-13

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 229

Registration Number: NCT04318210

Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda

Not Applicable

Completed

Conditions: Diphtheria
Pertussis
Polio
Haemophilus Influenzae Type b Infection
Tetanus
Measles
Hepatitis B

Interventions: Behavioral: SMS text reminders

First Posted Date: 2019-11-26

Last Posted Date: 2019-11-26

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 1962

Registration Number: NCT04177485

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy